Trulicity (Dulaglutide) Safety in Adolescents Ages 12, 17

Is Dulaglutide FDA-Approved for Adolescents Ages 12, 17?

Dulaglutide is not FDA-approved for adolescents ages 12, 17 as of July 2025. The FDA approved Trulicity for adults with type 2 diabetes (T2D) in September 2014 and later for cardiovascular risk reduction in adults, but no pediatric labeling extension has been granted for this age group. Prescribers considering dulaglutide for a 12-to-17-year-old patient are operating in off-label territory and carry the documentation and informed-consent responsibilities that accompany that status.

The FDA's pediatric drug development pathway under the Pediatric Research Equity Act (PREA) requires manufacturers to submit pediatric study plans when an adult indication exists. Eli Lilly has an active pediatric investigation for dulaglutide, but results sufficient to support a label change had not been published or accepted by the FDA at the time this article was reviewed. The FDA pediatric labeling database can be monitored for updates as data mature.

For comparison, liraglutide (Victoza, 1.8 mg once daily subcutaneous) received FDA approval for T2D in patients ages 10 and older in June 2019, making it the first GLP-1 receptor agonist with a pediatric T2D label in the United States [1]. That approval rested on the ELLIPSE trial, which enrolled 134 adolescents and demonstrated HbA1c reductions of 0.64% versus a 0.42% increase in the placebo arm over 26 weeks [1].

What the REWIND Trial Tells Us About Dulaglutide Safety

The REWIND trial (N=9,901 adults) is the cornerstone cardiovascular outcomes study for dulaglutide and provides the most rigorous long-term safety dataset available for the drug, even though it enrolled adults only. Published in The Lancet in 2019, REWIND showed a 12% relative reduction in major adverse cardiovascular events (MACE: non-fatal MI, non-fatal stroke, or CV death) with dulaglutide 1.5 mg weekly compared with placebo over a median 5.4 years [2].

The safety data from REWIND are relevant to adolescent prescribing decisions because they define the drug's adverse-event fingerprint at scale. Key findings:

• Gastrointestinal adverse events occurred in 47.4% of the dulaglutide group versus 34.1% placebo. Nausea was the most common single event, reported in 20.0% of the dulaglutide arm [2].
• Pancreatitis incidence was low and statistically similar between groups (0.4% dulaglutide vs. 0.3% placebo; hazard ratio 1.19 to 95% CI 0.69, 2.05) [2].
• Injection-site reactions occurred in 5.0% of participants on dulaglutide [2].
• No excess fracture risk or bone-density signal emerged over the 5.4-year follow-up [2].

Adolescents tolerate GI side effects differently from older adults. Nausea in a 14-year-old can affect school attendance, nutrient intake, and adherence in ways that a clinician treating an adult population might underestimate. The GI rate from REWIND should be treated as a floor estimate for adolescent counseling, not a ceiling.

How Does Dulaglutide Compare to Other GLP-1 Agents in Teens?

No head-to-head trial compares dulaglutide directly to semaglutide or liraglutide in adolescent T2D patients. The evidence hierarchy for GLP-1 use in ages 12, 17 is thin, and extrapolation from adult data remains the primary tool clinicians have.

Semaglutide 2.4 mg (Wegovy) received FDA approval for chronic weight management in adolescents ages 12 and older with obesity in December 2022, based on the STEP TEENS trial (N=201), which showed a 16.1% reduction in BMI at 68 weeks versus a 0.6% increase with placebo [3]. That trial is the best-powered adolescent GLP-1 dataset currently available and informs expectations for the drug class broadly.

Liraglutide, as noted above, has the only FDA-approved T2D indication in pediatric patients, and its safety profile across the ELLIPSE trial showed nausea in 64.2% of the liraglutide group versus 35.5% placebo over 26 weeks [1]. That rate is substantially higher than the adult REWIND figures for dulaglutide, reflecting both the nature of liraglutide's shorter half-life and the GI sensitivity common in adolescent populations.

Dulaglutide's once-weekly dosing with a fixed-dose pen device may offer adherence advantages over daily liraglutide in teenagers, a population for whom injection burden and routine complexity carry real behavioral weight. No trial has formally tested this hypothesis in adolescents.

Dosing Considerations for Adolescent Patients

Adolescents prescribed dulaglutide off-label are generally started at the same 0.75 mg once-weekly subcutaneous dose used in adults, with titration to 1.5 mg after four weeks if tolerated. The 3.0 mg and 4.5 mg doses approved for additional HbA1c reduction in adults lack any adolescent dosing data and should not be initiated in this age group outside a clinical trial.

Body weight affects drug exposure. A 45 kg adolescent will have higher dulaglutide plasma concentrations per kilogram than a 90 kg adult receiving the same 0.75 mg dose. Population pharmacokinetic modeling has not been published specifically for adolescents at dulaglutide's current approved doses, which is one reason the FDA has not granted pediatric labeling. Prescribers should account for low body weight when assessing nausea risk and should start at 0.75 mg without exception.

Injection technique matters especially in lean adolescents. The subcutaneous fat layer at the abdomen or thigh may be thinner than in adults, increasing the probability of inadvertent intramuscular injection. Clinicians should confirm proper site rotation and pinch technique at each visit.

The autoinjector pen used for Trulicity does not require manual needle attachment, which may reduce injection anxiety in younger patients. A brief in-office demonstration at initiation, followed by a return demonstration from the patient, reduces administration errors substantially in pediatric populations.

Growth, Puberty, and Nutritional Monitoring

Nausea-driven caloric restriction is the primary growth concern with GLP-1 use in adolescents. If a 13-year-old who is in an active pubertal growth phase reduces caloric intake by 300 to 500 kcal/day due to GLP-1-related nausea, the downstream effect on height velocity and lean-mass accrual may not be clinically apparent for six to twelve months.

Monitoring recommendations for adolescents on dulaglutide should include:

Height and weight. Measure every three months for the first year. Plot BMI-for-age on CDC growth charts. A decline in height-velocity percentile (e.g., dropping from the 50th to the 25th percentile of height-velocity for age) warrants nutrition referral and possible dose reduction.

Nutritional adequacy. A 24-hour dietary recall at each visit or a three-day food diary between visits gives an early signal for inadequate protein and micronutrient intake. Calcium and vitamin D status deserve attention given bone-mass accrual requirements during adolescence.

Pubertal staging. Tanner staging at initiation and annually allows the clinical team to contextualize any growth slowdown in relation to pubertal timing rather than attributing it reflexively to the medication.

The American Academy of Pediatrics and the Endocrine Society have not yet published specific monitoring guidelines for GLP-1 use in adolescents with T2D, leaving individual clinicians to apply adult T2D guidelines (such as the 2024 ADA Standards of Care) with developmental adaptations [4].

Mental Health Monitoring and the FDA Suicidality Signal

In 2023, the FDA issued a notice investigating reports of suicidal ideation and behavior in patients using GLP-1 receptor agonists, including semaglutide and liraglutide, after signals emerged in the FDA Adverse Event Reporting System (FAERS) [5]. The agency subsequently concluded in early 2024 that available data did not establish a causal relationship, but the monitoring framework established during that review period remains clinically relevant, especially for adolescents.

Adolescents with T2D already carry a higher baseline risk of depression and anxiety than their peers without chronic disease. A 2018 meta-analysis in Diabetes Care found that adolescents with T2D had approximately twice the rate of depressive symptoms compared to adolescents without diabetes [6]. Adding a medication that may cause nausea, reduced appetite, and body-image changes creates additional psychological load.

Clinicians should screen for depressive symptoms and suicidal ideation using a validated tool, such as the Patient Health Questionnaire-Adolescent (PHQ-A), at initiation and every three months during the first year of GLP-1 therapy. Any new or worsening suicidal ideation should prompt immediate evaluation independent of whether the medication is considered causal.

A practical monitoring framework for dulaglutide use in adolescents ages 12, 17 should include: PHQ-A screening at baseline, month 1, month 3, and then quarterly; weight and height at every visit; HbA1c at 3 and 6 months; a lipase level only if abdominal pain is reported; and a thyroid ultrasound only if a palpable thyroid nodule or neck mass is detected on exam. This framework does not replace individualized clinical judgment but gives a minimum-standard structure for off-label adolescent use.

Contraindications and Drug Interactions in Adolescent Patients

The contraindications for dulaglutide in adolescents are the same as in adults, because no pediatric-specific contraindication data exist:

Medullary thyroid carcinoma (MTC) history. GLP-1 receptors are expressed on thyroid C-cells in rodents, and dulaglutide caused dose-dependent thyroid C-cell tumors in rats and mice. Human relevance remains uncertain, but a personal or family history of MTC or Multiple Endocrine Neoplasia type 2 (MEN2) is an absolute contraindication per the FDA label [7].

Pancreatitis history. Prior acute pancreatitis is a relative contraindication. If a teen has had even a single episode of acute pancreatitis, the risk-benefit discussion must explicitly weigh the low but non-zero pancreatitis signal seen across the GLP-1 class.

Hypersensitivity. Any serious hypersensitivity reaction to dulaglutide or an excipient contraindicates re-exposure.

Drug interactions relevant to adolescents are primarily pharmacodynamic rather than pharmacokinetic. Dulaglutide slows gastric emptying, which can reduce the peak plasma concentration of oral medications taken concurrently. For a teenager on oral contraceptives or oral thyroid replacement, timing the medication away from the dulaglutide injection day by at least two to four hours may reduce this effect, though the clinical significance at standard GLP-1 doses is generally modest [7].

What Adolescents and Families Should Know About Injection Training

Most adolescents who start Trulicity have never self-administered an injection. The psychological barrier is real. Fear of needles affects an estimated 63% of children and adolescents in various survey studies, and that fear does not disappear automatically at age 12.

A structured injection-training protocol should include:

1. A nurse or clinical pharmacist demonstrating the Trulicity autoinjector on a silicone pad or training device before any medication is dispensed.
2. The patient performing a return demonstration on themselves (or a training pad, depending on comfort) before leaving the clinic.
3. A follow-up phone or telehealth check-in at day 7, after the first self-administered dose, to troubleshoot technique errors and address nausea management.

Nausea peaks in the first four to eight weeks at 0.75 mg. Practical strategies that reduce severity include injecting in the evening rather than the morning (so the worst nausea occurs during sleep), eating smaller and more frequent meals, and avoiding high-fat or spicy foods on injection day. These measures are not experimental; they reflect clinical practice patterns used in adult GLP-1 programs and are reasonable to apply in adolescents.

Thyroid Monitoring: What the Label Says and What Clinicians Do

The Trulicity prescribing information includes a black-box warning about thyroid C-cell tumors observed in rodent studies and advises clinicians to counsel patients about the theoretical risk of MTC and to inform them of symptoms (neck mass, dysphagia, dyspnea, persistent hoarseness) [7]. For adolescents, whose thyroid cancer incidence is already higher than in younger children, this counseling is especially concrete.

Routine thyroid ultrasound is not recommended in the absence of clinical findings. The American Thyroid Association's 2015 guidelines on thyroid nodules do not recommend population-level ultrasound screening for GLP-1 use [8]. Palpation of the thyroid at every visit, combined with a brief symptom review, is the appropriate monitoring standard.

Calcitonin measurement as a screening tool for MTC is discussed in the European dulaglutide label but is not recommended in the FDA label due to concerns about specificity. In adolescent patients with any family history of MEN2 or MTC, genetic counseling and RET proto-oncogene testing should precede any decision to use a GLP-1 receptor agonist.

HbA1c and Glycemic Outcomes: Setting Realistic Expectations

Adult trials provide the best available estimate of glycemic efficacy for dulaglutide in adolescents. In the AWARD-5 trial (N=807 adults with T2D), dulaglutide 1.5 mg produced a placebo-adjusted HbA1c reduction of 1.1% at 52 weeks [9]. The AWARD-11 trial (N=1,842 adults) showed that 3.0 mg and 4.5 mg doses produced HbA1c reductions of 1.87% and 2.02%, respectively, versus 1.36% with 1.5 mg at 36 weeks [10].

For adolescents, the ADA's 2024 Standards of Care recommend an HbA1c target of <7.0% for most teens with T2D if achievable without significant hypoglycemia [4]. Dulaglutide monotherapy at 0.75 to 1.5 mg may be sufficient to reach that target in adolescents with newly diagnosed T2D and residual beta-cell function, but combination with metformin is common in adults and would likely be the first-line backbone in off-label adolescent use as well.

Hypoglycemia risk with dulaglutide monotherapy is low because GLP-1 receptor agonists stimulate insulin secretion in a glucose-dependent manner. In REWIND, severe hypoglycemia occurred in 2.0% of the dulaglutide group over 5.4 years, with most events occurring in participants also taking sulfonylureas or insulin [2]. Adolescents on dulaglutide without sulfonylureas or insulin have a low intrinsic hypoglycemia risk from the drug itself.

Shared Decision-Making and Documentation for Off-Label Use

Prescribing dulaglutide to a 12-to-17-year-old requires explicit informed consent that covers both the absence of FDA approval for this age group and the known risks. The medical record should document:

• The clinical rationale for choosing dulaglutide over an FDA-approved alternative (e.g., why not liraglutide or metformin as first steps).
• A discussion of risks specific to adolescents, including growth effects, GI burden, and the mental health monitoring requirement.
• Patient and caregiver understanding of injection technique, storage requirements (refrigerated at 36, 46°F, or up to 14 days at room temperature not exceeding 86°F), and the importance of reporting persistent abdominal pain within 48 hours.

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy recommends GLP-1 receptor agonists as first-line pharmacotherapy for adolescent obesity complicating T2D when lifestyle intervention is insufficient, while acknowledging that the evidence base for specific agents in teens remains limited [11].

"The selection of a particular GLP-1 receptor agonist for an adolescent patient should be guided by the available evidence for that specific agent in pediatric populations, with preference given to agents that have completed randomized controlled trials in the relevant age group," according to language adapted from the Endocrine Society's obesity pharmacotherapy guidance [11].